Exagen Inc (NASDAQ:XGN) shares, rose in value on Thursday, May 08, with the stock price down by -9.81% to the previous day’s close as strong demand from buyers drove the stock to $6.16.
Actively observing the price movement in the last trading, the stock closed the session at $6.83. Referring to stock’s 52-week performance, its high was $7.20, and the low was $1.35. On the whole, XGN has fluctuated by 54.00% over the past month.
With the market capitalization of Exagen Inc currently standing at about $110.90 million, investors are eagerly awaiting this quarter’s results, scheduled for in June.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 65.86M, with a low estimate of 15.4M and a high estimate of 16.64M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 16.23M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that XGN’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium-term indicators have put the stock in the category of 100% Buy while long-term indicators on average have been pointing out that it is a 100% Buy.
The stock’s technical analysis shows that the price of XGN currently trading nearly 10.90% and 38.92% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 59.70, while the 7-day volatility ratio is showing 13.41% which for the 30-day chart, stands at 11.30%. Furthermore, Exagen Inc (XGN)’s beta value is 1.59, and its average true range (ATR) is 0.64.
A comparison of Exagen Inc (XGN) with its peers suggests the former has fared considerably weaker in the market. XGN showed an intraday change of -9.81% in last session, and over the past year, it grew by 346.38%%.
Data on historical trading for Exagen Inc (NASDAQ:XGN) indicates that the trading volumes over the past 3 months, they’ve averaged 129.83K. According to company’s latest data on outstanding shares, there are 17.95 million shares outstanding.
Nearly 48.77% of Exagen Inc’s shares belong to company insiders and institutional investors own 34.03% of the company’s shares. The stock has risen by 50.24% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the XGN stock heading into the next quarter.
